CTLA4 and hepatocellular carcinoma: Our HCC therapeutic regimen consisted of two arms: one was to promote antitumor immune host responses using a combination of HMGN1 and R848; the other aimed to disarm immunosuppression, by using checkpoint inhibitors anti-PD-L1 and anti-CTLA4 or low dose of CY to reduce Treg function.